Skin & Soft Tissue Diseases

The FDA advisory committee voted 17 to 1 in favor of omadacycline for treatment of ABSSSI and 14 to 4 for the treatment of CABP.

Following cases of vibriosis in New Jersey, Alabama, and Florida, health officials are telling individuals with open wounds to stay out of coastal or brackish waters.

Development of the drug has been deemed necessary because of the potential for the use of the virus in a bioterrorism attack and waning herd immunity against the virus among the general population.

Preliminary studies provide convincing evidence for the synergistic use of sulfonamide agents with azole antifungals.

Research presented at the 2018 ASM Microbe Meeting has reinforced the value of the just-approved next-generation aminoglycoside antibiotic, plazomicin, in treating multidrug-resistant Enterobacteriaceae.

Because of the global rise in antimicrobial resistance, meropenem-vaborbactam, the first carbapenem/β-lactamase combina­tion medication, is a welcome new antibac­terial.

Skin and soft tissue infections appear to be on the decline in the general population, but individuals with HIV have a higher risk.

Several recent studies provide valuable insight surrounding the appropriateness of transitioning from intravenous to oral therapy when treating bacteremic urinary tract infections.

Researchers present positive new data from multiple studies of VIBATIV at the 2018 ECCMID conference in Madrid, Spain.